Closing the data loop in AI-driven drug discovery
Emerging AI-driven research infrastructure raises long-run questions about data standards and regulatory readiness - background context for science policy teams.
Key points
- AI-driven drug discovery still lacks FDA-approved outputs, though experts expect that to change within three years.
- Autonomous 'dark labs' cycling prediction, testing, and optimisation represent an emerging frontier in AI-enabled science.
- Limited direct relevance to APS AI governance practitioners - primarily a life-sciences industry and R&D item.
View original source
Copied.
"Closing the data loop in AI-driven drug discovery"
Source: MIT Technology Review – AI
Published: 27 July 2026
URL: https://www.technologyreview.com/2026/07/27/1139667/closing-the-data-loop-in-ai-driven-drug-discovery/
MIT Technology Review reports on the state of AI-driven drug discovery, covering autonomous laboratory systems that integrate AI prediction with physical experimentation in continuous feedback loops. Key themes include data interoperability (FAIR principles), scientific image integrity tooling, and the barriers - regulatory, cost, and model maturity - still preventing full in silico drug development. No AI-primarily-discovered drug has yet received full FDA approval, though industry observers expect this within two to three years.
Retrieved from SIMS, 16 September 2026.